We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Rudolf de Boer

Rudolf A. de Boer MD, PhD

Director, Experimental Cardiology, Professor of Cardiology, University of Groningen, Department of Cardiology, University Medical Center Groningen, the Netherlands

Rudolf de Boer (1972, Gouda, the Netherlands) is a Clinical Cardiologist, a Full Professor of Translational Cardiology, and the Director of the Experimental Cardiology at the University Medical Center Groningen, the Netherlands (https://www.groningencardiology.com).

He studied medicine at the University of Groningen and, previous to his current appointment, completed a research fellowship at the University of Utah, Salt Lake City, USA, a PhD program at the University of Groningen, and a post-doctoral fellowship at Harvard Medical School, Boston, USA.

His research group focuses on novel genes involved in cardiac remodeling and heart failure, fibrosis, metabolic changes, and diabetes, always trying to connect clinical observations to preclinical and mechanistic studies. The last 10 years, he has studied biomarkers in clinical heart failure and in the general population, and focused on their role in the pathophysiology of heart failure. Recently he focuses on interaction of heart failure and co-morbidities, including cancer. He has been was a founding member the scientific committee of LifeLines, a population study of 165,000 subjects of the Northern part of the Netherlands. Doctor de Boer’s clinical interests are cardiogenetics, echocardiography and end-stage heart failure including VAD therapy and transplant.

Dr. de Boer has authored and co-authored over 350 articles in peer reviewed journals (https://www.ncbi.nlm.nih.gov/pubmed/?term=de+boer+ra) and wrote over 10 book chapters. He received grants from the Netherlands Heart Foundation, the Dutch Organization for Scientific Research, and the European research Council (ERC).

He was appointed a Fellow of the European Society of Cardiology (ESC) in 2010. He has served as the president of the Heart Failure Working Group of the Dutch Society of Cardiology from 2014-2019, and since 2014 is Board Member of the Heart Failure Association (HFA) of the ESC. He is coordinator of the HFA committee on Heart Failure with Preserved Ejection Fraction (HFpEF) and co-coordinator of the translational Committee. He is a member of the ESC Education, Advocacy, and eHealth committees.

Dr. de Boer has been an Associate Editor of the European Journal of Heart Failure since 2009 and is a  member of the editorial board of Cardiovascular Research, as well as being ad-hoc reviewer for several journals, including Circulation, Journal of the American College of Cardiology, and the European Heart Journal.

Disclosures

The UMCG, which employs Dr. De Boer, has received research grants and/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Novo Nordisk, and Roche.
Dr. de Boer received speaker fees from Abbott, AstraZeneca, Novartis, and Roche.